CAR-T细胞疗法在食管癌治疗中的研究进展  

Research Progress of CAR-T Cell Therapy in the Treatment of Esophageal Cancer

作　　者：安艳辉 翟景明[1] 杨如月 庞天舒 梁高峰[2] AN Yanhui;ZHAI Jingming;YANG Ruyue;PANG Tianshu;LIANG Gaofeng(The First Affiliated Hospital of Henan University,Henan Key Laboratory of Cancer Epigenetics,Luoyang,China,471023;School of Basic Medicine and Forensic Medicine,Henan University of Science&Technology,Luoyang,China,471023)

机构地区：[1]河南科技大学第一附属医院,河南省肿瘤表观遗传学重点实验室,洛阳471023 [2]河南科技大学基础医学与法医学院,洛阳471023

出　　处：《食管疾病》2025年第1期16-20,41,共6页Journal of Esophageal Diseases

基　　金：洛阳市公益性行业医疗卫生专项(2202004A);河南省重点研发专项(221111310600);河南省科技攻关项目(222103810047)。

摘　　要：嵌合抗原受体修饰T细胞(chimeric antigen receptor T cells,CAR-T)疗法在血液肿瘤中表现出良好的治疗效果,同时,针对实体瘤的CAR-T细胞研究也表现出很好的潜力。食管癌(esophageal cancer,EC)在我国发病率及死亡率均位居前列,传统手术及放化疗均有不同程度的缺点,亟需新的治疗手段来弥补当前治疗的不足。本文就CAR-T疗法在食管癌治疗中亟需解决的问题及其应对策略来展开论述,以期为食管癌基础及临床研究提供参考。Chimeric antigen receptor T cells(CAR-T)therapy has shown good therapeutic effects in hematological malignancies.At the same time,CAR-T cells for solid tumors also show great potential.Esophageal cancer has a high incidence and mortality rate in China.Traditional surgery,radiotherapy and chemotherapy have varying degrees of shortcomings.It is an urgent need for new treatment methods to make up for the shortcomings of current treatment.In this review,the problems and coping strategies of CAR-T theranostics in the treatment of esophageal cancer are discussed,to provide reference for the basic and clinical research of esophageal cancer.

关 键 词：CAR-T 食管癌 脱靶效应 肿瘤微环境 

分 类 号：R735[医药卫生—肿瘤]